This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (96)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Review  • Psoriasis  • Immunotherapy  • Alert me on articles by topic

The Drug for the Turn of the Millennium?

Thomas Ruzicka, MD; Till Assmann, MD; Bernhard Homey, MD

Arch Dermatol. 1999;135:574-580.

Background  Tacrolimus has been shown to be a powerful suppressor of the immune system. It was introduced into clinical use to prevent allograft rejection and is now routinely used in kidney, liver, and heart transplantation. Recently, 2 double-blind multicenter studies demonstrated the therapeutic efficacy of topical and systemic tacrolimus in the inflammatory skin diseases atopic dermatitis and psoriasis.

Data Source  MEDLINE was searched for relevant publications and combined with our own clinical, in vitro, and in vivo studies.

Study Selection  All studies dealing with tacrolimus and dermatology were reviewed.

Data Extraction  Publications with clinically relevant data were included in this review.

Conclusions  Topical tacrolimus is a safe and effective therapeutic agent that may open a new era in the treatment of inflammatory skin diseases, particularly for patients with atopic dermatitis. Before its full potential in dermatology can be assessed, more clinical experience in treating children and comparison with the criterion standard of anti-inflammatory therapy, glucocorticosteroids, are needed.

From the Department of Dermatology, University of Düsseldorf, Düsseldorf, Germany.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Recalcitrant Symptomatic Vulvar Lichen Planus: Response to Topical Tacrolimus
Byrd et al.
Arch Dermatol 2004;140:715-720.
ABSTRACT | FULL TEXT  

A Case of Generalized Pustular Psoriasis Treated With Topical Tacrolimus
Ishiko et al.
Arch Dermatol 2003;139:1219-1219.
FULL TEXT  

Successful Treatment of Anogenital Lichen Sclerosus With Topical Tacrolimus
Bohm et al.
Arch Dermatol 2003;139:922-924.
ABSTRACT | FULL TEXT  

A Double-blind Randomized Trial of 0.1% Tacrolimus vs 0.05% Clobetasol for the Treatment of Childhood Vitiligo
Lepe et al.
Arch Dermatol 2003;139:581-585.
ABSTRACT | FULL TEXT  

Childhood Vitiligo and Tacrolimus: Immunomodulating Treatment for an Autoimmune Disease
Plettenberg et al.
Arch Dermatol 2003;139:651-654.
FULL TEXT  

Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis
Allen and Esterly
Arch Dermatol 2002;138:1259-1260.
FULL TEXT  

Successful Treatment of Erosive Lichen Planus With Topical Tacrolimus
Lener et al.
Arch Dermatol 2001;137:419-422.
FULL TEXT  

Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations
Ting and Sontheimer
Lupus 2001;10:171-184.
ABSTRACT  

Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease
Casson et al.
Gut 2000;47:436-440.
ABSTRACT | FULL TEXT  

Psoriatic arthritis, nail disease and pustules following Hodgkin's lymphoma
Kallarackal and Jones
Rheumatology (Oxford) 2000;39:930-931.
FULL TEXT  

Recent advances: Dermatology
Foley
BMJ 2000;320:850-853.
FULL TEXT  

Recent Therapeutic Advances in Dermatology
Lipper et al.
JAMA 2000;283:175-177.
FULL TEXT  

Topical Tacrolimus: Treatment Failure in a Patient With Alopecia Areata
Thiers
Arch Dermatol 2000;136:124-124.
FULL TEXT